Dipharma Launches Sapropterin Dipharma in the EU and Switzerland
Shots:
- The company reported the commercial availability of Sapropterin Dipharma in main EU countries and in Switzerland. The product is available in the form of soluble tablets of 100mg, powder for oral solutions of 100 & 500mg
- Sapropterin Dipharma is a generic equivalent to Kuvan and indicated for the treatment of BH4 deficiency and BH4-responsive phenylketonuria (PKU) patients. Sapropterin formulations are approved for the treatment of patients with BH4-responsive phenylketonuria and BH4 deficiency
- Sapropterin Dipharma is distributed directly by Dipharma in Switzerland via Dipharma subsidiary Arzneimittel GmbH in Germany, and by a network of reputable selected partners in the other EU countries
Ref: Dipharma | Image: Dipharma
Related News:- Celltrion Launches Yuflyma (biosimilar, adalimumab) in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
